Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Insulin Formulations: Types and Delivery

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

Type II Diabetes I: Introduction

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Treatment Algorithm for Patients with Obesity in India: A Joint Consensus by Endocrine Society of India and Obesity Surgeons Society of India.

Obesity surgery·2026

Same author

Impact of Simulated Risk Factor Management on Cardiovascular Disease and Costs in Type 2 Diabetes Using the ABC Model.

Diabetes, obesity & metabolism·2026

Same author

Optimizing Continuous Glucose Monitoring Adoption in India: From Current Challenges to Future Solutions.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2026

Same author

Efficacy and safety of fixed-dose dapagliflozin-pioglitazone in Indian adults with type 2 diabetes: a phase 3 PRO-1 trial.

Diabetology & metabolic syndrome·2026

Same author

Evidence-Based Guidelines for Intravitreal Anti-VEGF Therapy for Diabetic Retinopathy in Chronic Kidney Disease.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2025

Same author

The Proteome Profile of Stress Test Assessed Cardiovascular Disease Risk-Prone Diabetic Subjects.

Journal of cardiovascular translational research·2025

Search research articles

Related Experiment Video

Updated: May 31, 2026

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Recommendations for insulin initiation based on ethnicity.

M John¹, S Kalra, A G Unnikrishnan

¹Providence Endocrine & Diabetes Specialty Centre, Near GG Hospital, Trivandrum, India. drmathewjohn@yahoo.com

Medical Hypotheses

|July 12, 2011

Summary

This summary is machine-generated.

Many type 2 diabetes patients in the USA struggle with glycemic control. This study questions if current guidelines adequately consider ethnic differences in treatment, particularly for insulin therapy.

More Related Videos

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults

Published on: December 1, 2023

Electrochemiluminescence Assays for Human Islet Autoantibodies

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

Related Experiment Videos

Last Updated: May 31, 2026

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults

Published on: December 1, 2023

Electrochemiluminescence Assays for Human Islet Autoantibodies

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

Area of Science:

Endocrinology
Pharmacology
Public Health

Background:

Despite numerous anti-diabetic medications, many type 2 diabetes patients in the USA do not achieve adequate glycemic control.
Current clinical practice guidelines from organizations like ADA, EASD, and CDA aim to standardize treatment but may not account for population-specific factors.

Purpose of the Study:

To evaluate the appropriateness of current type 2 diabetes treatment guidelines from an ethnopharmacy perspective.
To explore whether racial and ethnic variations necessitate tailored therapeutic approaches, especially for insulin therapy.

Main Methods:

Review of existing clinical practice guidelines for type 2 diabetes management.
Analysis of known racial and ethnic differences in pathophysiology, including insulin resistance, diet, glucose metabolism, and genetics.
Comparative evaluation of guideline recommendations against ethnopharmacological considerations.

Main Results:

Significant racial and ethnic variations exist in key diabetes-related parameters.
Current guidelines may offer a one-size-fits-all approach that overlooks these critical differences.
The study postulates that ethnic characteristics should influence the choice of insulin therapy.

Conclusions:

Standardized type 2 diabetes treatment guidelines may not be universally optimal due to unaddressed ethnic variations.
An ethnopharmacy approach is crucial for refining treatment strategies, particularly insulin therapy, to improve glycemic control in diverse populations.
Personalized treatment plans considering ethnic profiles are likely more effective than broad recommendations.